4-[5-ethoxy-4-(1-methylindazol-5-yl)-1-(piperidin-3-ylmethyl)pyrazol-3-yl]-2-fluorobenzonitrile
C26H27FN6O — CID 169102660
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[5-ethoxy-4-(1-methylindazol-5-yl)-1-(piperidin-3-ylmethyl)pyrazol-3-yl]-2-fluorobenzonitrile
4-[5-ethoxy-4-(1-methylindazol-5-yl)-1-(piperidin-3-ylmethyl)pyrazol-3-yl]-2-fluorobenzonitrile (PubChem CID 169102660) has the molecular formula C26H27FN6O and a molecular weight of 458.54 g/mol. Its IUPAC name is 4-[5-ethoxy-4-(1-methylindazol-5-yl)-1-(piperidin-3-ylmethyl)pyrazol-3-yl]-2-fluorobenzonitrile.
Molecular Properties
| Compound Name | 4-[5-ethoxy-4-(1-methylindazol-5-yl)-1-(piperidin-3-ylmethyl)pyrazol-3-yl]-2-fluorobenzonitrile |
|---|---|
| PubChem CID | 169102660 |
| Molecular Formula | C26H27FN6O |
| Molecular Weight | 458.54 g/mol |
| Exact Mass | 458.22 |
| IUPAC Name | 4-[5-ethoxy-4-(1-methylindazol-5-yl)-1-(piperidin-3-ylmethyl)pyrazol-3-yl]-2-fluorobenzonitrile |
| SMILES | CCOc1c(-c2ccc3c(cnn3C)c2)c(-c2ccc(C#N)c(F)c2)nn1CC1CCCNC1 |
| InChI | InChI=1S/C26H27FN6O/c1-3-34-26-24(18-8-9-23-21(11-18)15-30-32(23)2)25(19-6-7-20(13-28)22(27)12-19)31-33(26)16-17-5-4-10-29-14-17/h6-9,11-12,15,17,29H,3-5,10,14,16H2,1-2H3 |
| InChIKey | VCRCKJJWXXABLY-UHFFFAOYSA-N |
| XLogP | 4.51 |
| TPSA | 80.69 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 458.54 |
| LogP ≤ 5 | 4.51 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 169102660 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.